Prostate Adenocarcinoma Clinical Trials

40 studies are recruiting for prostate adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

   To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   10 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT05751434 on ClinicalTrials.gov

2. Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

   This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Sean Sachdev

   See if you can join NCT06499870 on ClinicalTrials.gov

3. Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

   This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg dai…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   5 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06022822 on ClinicalTrials.gov

4. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

   This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   436 in total

   Run by

   NRG Oncology

   See if you can join NCT05946213 on ClinicalTrials.gov

5. Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

   This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging …

   Stage

   Phase 4

   Ages

   18 and older

   Site

   OHSU Knight Cancer Institute, Portland, Oregon

   Run by

   OHSU Knight Cancer Institute

   See if you can join NCT05919329 on ClinicalTrials.gov

6. Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

   Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of p…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05616650 on ClinicalTrials.gov

7. Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

   This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emission tomography (PET)/computed tomography (CT) in patients wit…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT07025369 on ClinicalTrials.gov

8. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beverly Hills Cancer Center, Beverly Hills, California

   Locations

   37 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov

9. Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

   This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low vol…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07650240 on ClinicalTrials.gov

10. Two-fraction HDR Monotherapy for Localized Prostate Cancer

    This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 frac…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT05665738 on ClinicalTrials.gov

11. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

    Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    4 in total

    Run by

    University of Chicago

    See if you can join NCT05726292 on ClinicalTrials.gov

12. High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

    This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cel…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California at Los Angeles / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT04945642 on ClinicalTrials.gov

13. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective c…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Anchorage Associates in Radiation Medicine, Anchorage, Alaska

    Locations

    341 in total

    Run by

    ECOG-ACRIN Cancer Research Group

    See if you can join NCT04423211 on ClinicalTrials.gov

14. Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

    The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims to answer are: * Does fezolinetant improve the frequency and severity of hot flashes? * Does fezolin…

    Stage

    Phase 2

    Ages

    40 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Shehzad Basaria, M.D.

    See if you can join NCT06957691 on ClinicalTrials.gov

15. Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

    The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

    Stage

    Phase 1

    Ages

    21 and older

    Site

    Urology Associates of Central California, Fresno, California

    Locations

    10 in total

    Run by

    Alessa Therapeutics Inc.

    See if you can join NCT06257693 on ClinicalTrials.gov

16. Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

    This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer.…

    Stage

    Phase 2

    Ages

    Any age

    Site

    Beckman Research Institute of the City of Hope, Duarte, California

    Locations

    3 in total

    Run by

    Stephen Freedland

    See if you can join NCT05832086 on ClinicalTrials.gov

17. Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

    This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT05610852 on ClinicalTrials.gov

18. Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

    The goal of this clinical trial is to study definitive external beam radiation therapy together with drugs called androgen deprivation therapy (ADT) in patients with prostate cancer. The investigators want to find out if these drugs work the same way if they are given for 6 months or for the usual …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California San Diego, La Jolla, California

    Run by

    University of California, San Diego

    See if you can join NCT07364071 on ClinicalTrials.gov

19. Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

    This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs the hormone testosterone to grow. Apalutamide is a hormone therapy that blocks the effect of testos…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT06067269 on ClinicalTrials.gov

20. Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

    This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may hel…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

    Locations

    2 in total

    Run by

    University of Washington

    See if you can join NCT04175431 on ClinicalTrials.gov

21. rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

    This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT05852041 on ClinicalTrials.gov

22. An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

    This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following prior treatment (biochemical recurrence) but who were prostate specifi…

    Stage

    EARLY_Phase 1

    Ages

    Any age

    Site

    Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT06813898 on ClinicalTrials.gov

23. A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

    The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07635238 on ClinicalTrials.gov

24. PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

    The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3.…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT06392295 on ClinicalTrials.gov

25. The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

    Researchers are trying to determine whether there is additional utility to using vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile function (recovery) after prostate…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT05109208 on ClinicalTrials.gov